Radioligand Therapy Market, Global Outlook and Forecast 2023-2028

Report ID: 1658254 | Published Date: Jan 2025 | No. of Page: 60 | Base Year: 2024 | Rating: 4.9 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%)

This report contains market size and forecasts of Radioligand Therapy in Global, including the following market information:
Global Radioligand Therapy Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Radioligand Therapy market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Actinium 225 (Ac-225) Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Radioligand Therapy include Novartis, Advanced Accelerator Applications, Mercy Radiology, POINT Biopharma Global Inc, Fusion Pharma, Telix Pharmaceuticals Ltd, Lantheus Holdings, Inc, Bayer AG and Curium Pharma and etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Radioligand Therapy companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Radioligand Therapy Market, by Used Radionuclides, 2017-2022, 2023-2028 ($ millions)
Global Radioligand Therapy Market Segment Percentages, by Used Radionuclides, 2021 (%)
Actinium 225 (Ac-225)
Lutetium 177 (Lu-177)
Gallium 68 (Ga-68)
Fluorine 18 (F-18)
Other Radionuclides
Global Radioligand Therapy Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Radioligand Therapy Market Segment Percentages, by Application, 2021 (%)
Neuroendocrine Neoplasms
Prostate Cancer
Global Radioligand Therapy Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Radioligand Therapy Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Radioligand Therapy revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Radioligand Therapy revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Novartis
Advanced Accelerator Applications
Mercy Radiology
POINT Biopharma Global Inc
Fusion Pharma
Telix Pharmaceuticals Ltd
Lantheus Holdings, Inc
Bayer AG
Curium Pharma
Precirix

Frequently Asked Questions
Radioligand Therapy Market report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Radioligand Therapy Market report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Radioligand Therapy Market report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports